Fidelity Investments’s Loncar China BioPharma ETF CHNA Stock Holding History

Fidelity Investments’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	5109
2021 Q3	$0	Buy	+1	New	+$41	﹤0.01%	5231

Other funds holding CHNA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Fidelity Investments's CHNA Position: Q4 2021 in Review

Fidelity Investments sold out of Loncar China BioPharma ETF (CHNA) in Q4 2021, closing a stake of 1 share.

Fidelity Investments first reported a position in CHNA in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 4 funds tracked by Wall St. Rank hold CHNA as of Q4 2021.

Fidelity Investments reported no remaining Loncar China BioPharma ETF position as of Q4 2021 after selling out during the quarter.
Fidelity Investments sold 1 Loncar China BioPharma ETF share in Q4 2021.
Fidelity Investments first reported a position in Loncar China BioPharma ETF in Q3 2021 and held it in 1 quarter.
Fidelity Investments's Loncar China BioPharma ETF position peaked at $0 in Q3 2021.
4 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q4 2021.

Based on Fidelity Investments's 13F filing for Q4 2021, filed 14 Feb 2022.